TIRZEPATIDE, 10 mg

Tirzepatide is a synthetic dual‑agonist peptide studied for its simultaneous activation of GLP‑1 and GIP receptors—two key pathways involved in blood‑sugar regulation, insulin sensitivity, and fat‑metabolism control. Research interest has grown rapidly due to its strong metabolic effects, including significant reductions in body weight and improvements in glucose handling.

Key Research Areas

• Dual GLP‑1/GIP receptor activation — Investigated for synergistic effects on glucose regulation and metabolic signaling.
• Weight‑management models — Research links tirzepatide to reduced appetite, increased satiety, and slowed gastric emptying, contributing to significant weight‑loss outcomes in controlled studies.
• Insulin sensitivity — Explored for its ability to improve insulin response and support glucose utilization.
• Comparative incretin research — Frequently evaluated alongside GLP‑1–only analogs to understand the advantages of dual‑pathway engagement.

⚠️ For Research Use Only
This product is not for human or veterinary use. It is intended strictly for laboratory research. Any mention of effects is based on scientific literature and does not imply approval by Health Canada or any regulatory agency